本研究是关于肝细胞癌（ HCC ）患者在肝切除或消融后肿瘤复发风险较高的辅助治疗测试的可行性研究。通过在手术过程中收集个别患者的肝脏和肿瘤组织，将采用3D生物列印技术来构建患者特定的仿生肝模型- “Liver-in-Cube” ，以测试和确定对个体最有效的辅助疗法
适应症：HCC - Hepatocellular Carcinoma
入组条件
纳入标准
- Age ≥ 18 years at the time of screening
- Diagnosis of HCC
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1
- With or without prior locoregional therapy such as transarterial chemoembolisation (TACE), radiofrequency ablation (RFA), and stereotactic body radiation therapy (SBRT) before surgery - Meet any item indicating higher risk of tumour recurrence: any tumour size ≥ 5cm, number of tumour ≥ 3, presence of microvascular or marcovascular invasion, or poor tumour differentiation
- No prior systemic therapy for HCC
- No other active malignancies within 5 years, except malignancies with a negligible risk of metastasis or death (eg. 5-year overall survival rate \> 90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localised prostate cancer, ductal carcinoma in situ, or stage I uterine cancer
- Willing and able to provide written informed consent for the collection and usage of biological samples
排除标准
- Non-HCC diagnosis, including fibrolamellar HCC, sarcomatoid HCC, mixed HCC cholangiocarcinoma etc.
- Fail to give consent or refusal to take part in the study
- Child-Pugh class C liver cirrhosis
- Receipt of any prior systemic therapy for HCC
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。